AI illustration · not actual product photoDetails from the source.
Source-listed Cagrilintide 5mg+Semaglutide 5mg (SKU CS10): 10mg*10vials. PriceList(1).pdf lists 152 per 10 vials but does not specify currency; the website displays $152 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- CS10
- Source specification
- 10mg*10vials
- Source document
- PriceList(1).pdf, page 4
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The named substances are peptide-based analogues, so this is a peptide-analogue blend as listed. The actual contents, manufacturer, formulation and status of SKU CS10 are not independently verified. Do not label it compounded or research-only without product-specific evidence.
Biological mechanism
Cagrilintide is a long-acting amylin analogue engaging amylin-receptor and calcitonin-receptor-family signaling. Semaglutide activates the GLP-1 receptor, a pathway involved in appetite and calorie intake, glucose-dependent insulin and glucagon regulation, and delayed gastric emptying. Laboratory receptor-structure findings support cagrilintide binding/activation biology, not clinical benefit for this specific vial. The combination's proposed complementary pathways do not establish effects for SKU CS10. [1] [2]
Research focus
Human studies have investigated cagrilintide plus semaglutide for body-weight management in adults with overweight or obesity and for weight and glycemic outcomes in adults with type 2 diabetes and overweight or obesity. The cited trials concern defined investigational study formulations, not a verified CS10 vial. [3] [4] [5]
Potential applications in the evidence
Potential applications under investigation include body-weight management in adults with overweight or obesity and weight/glycemic outcomes in adults with type 2 diabetes. These are research contexts, not established medical uses for this catalogue product; trial results do not verify this supplier-specific vial. [3] [4]
Human evidence
In the 68-week REDEFINE 1 Phase 3 trial in adults without diabetes, estimated mean weight change was −20.4% with the studied combination and −3.0% with placebo; gastrointestinal adverse events occurred in 79.6% and 39.9%, respectively. In the 68-week REDEFINE 2 trial in adults with type 2 diabetes, mean weight change was −13.7% versus −3.4%, and 73.5% versus 15.9% had HbA1c of 6.5% or less; gastrointestinal events occurred in 72.5% versus 34.4%. An earlier small Phase 1b study primarily assessed short-term safety, tolerability and pharmacokinetics, and its authors called for larger and longer trials. These findings establish human study of a defined combination, not efficacy, safety, equivalence or approval for SKU CS10. [3] [4] [5]
Known and potential effects
Combination trials reported common gastrointestinal adverse events, including nausea, vomiting, diarrhea, constipation and abdominal pain, mainly described as transient and mild to moderate. The FDA WEGOVY label for specified semaglutide products lists nausea, diarrhea, vomiting, constipation, abdominal pain, headache and other adverse reactions, and warnings including pancreatitis, gallbladder disease, hypoglycemia with insulin or insulin secretagogues, kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity, diabetic retinopathy complications, increased heart rate and pulmonary aspiration during anesthesia or deep sedation. These label data do not establish the risk profile of the catalogue vial. [1] [3] [4]
Safety and contraindications
The WEGOVY label contraindicates its semaglutide products for people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or known hypersensitivity to semaglutide or listed excipients. It warns that the human relevance of thyroid C-cell tumors observed in rodents is unknown, notes potential fetal harm and advises against use in severe gastroparesis. These statements apply to the specified FDA-labeled WEGOVY products, not to an approved label for this blend. Exact-vial composition, excipients, interactions, sterility, stability and risk profile are not verifiable from the catalogue. [1]
U.S. FDA / regulatory status
FDA has approved specific semaglutide-branded products for labeled indications; that approval does not transfer to cagrilintide, a combination, or this supplier-specific vial. Novo Nordisk reported that its CagriSema weight-management application was submitted to FDA in December 2025; its September 2026 investor presentation said a U.S. decision was expected in Q4 2026. Sources reviewed do not establish whether a decision had issued by 2026-10-30, so the combination's exact U.S. approval status on that date is unverified here. No source identifies the CS10 manufacturer, lot, formulation source, jurisdiction, or approval/authorization. [1] [6]
Evidence limitations
Mechanistic receptor studies are laboratory findings, distinct from animal or human outcomes. The cited Phase 3 trials studied a defined formulation in selected trial populations for 68 weeks, not a supplier vial with undocumented contents and manufacturing. Their results do not verify bioequivalence, purity, sterility, stability or benefit-risk for CS10. Some cited trials were sponsor-funded. The catalogue omits currency and does not fully clarify how the + label relates to the package specification *10vials. Exact SKU composition and regulatory authorization remain unverified.
Supporting sources
- WEGOVY semaglutide prescribing information U.S. Food and Drug Administration · FDA prescribing information. Supports: Semaglutide-specific FDA-approved product indications, mechanism, contraindications, warnings and adverse reactions; distinguishes labeled WEGOVY formulations from the catalogue vial.
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors Nature Communications · Peer-reviewed receptor structural study. Supports: Cagrilintide receptor mechanism and laboratory structural evidence; supports the distinction between mechanistic and clinical findings.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine / PubMed · Peer-reviewed Phase 3 randomized clinical trial. Supports: REDEFINE 1 population, 68-week weight outcomes and gastrointestinal adverse-event rates for the defined study combination.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine / PubMed · Peer-reviewed Phase 3 randomized clinical trial. Supports: REDEFINE 2 human weight and HbA1c outcomes and gastrointestinal adverse-event rates in adults with type 2 diabetes.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2· for weight management The Lancet / PubMed · Peer-reviewed Phase 1b randomized clinical trial. Supports: Early human combination tolerability and pharmacokinetics, study limitations, and need for larger and longer studies.
- Novo Nordisk Capital Markets Day 2026 obesity presentation Novo Nordisk · Official sponsor investor presentation. Supports: Sponsor's September 2026 statement that a U.S. decision on CagriSema weight management was expected in Q4 2026; does not establish that a decision had issued by October 30.